ANTX
AN2 Therapeutics Inc

360
Mkt Cap
$32.33M
Volume
38,861.00
52W High
$1.55
52W Low
$1.01
PE Ratio
-1.05
ANTX Fundamentals
Price
$1.19
Prev Close
$1.18
Open
$1.12
50D MA
$1.17
Beta
0.81
Avg. Volume
77,831.58
EPS (Annual)
-$1.72
P/B
0.54
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
AN2 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business and Scientific Highlights
AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today reported...
Business Wire·29d ago
News Placeholder
More News
News Placeholder
AN2 Therapeutics Announces Research Collaboration With GSK to Advance Boron-Based LeuRS-Inhibitors Targeting Tuberculosis (TB)
AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company advancing novel small molecule therapeutics through its boron chemistry platform, today announced a collaboration agreement with the...
Business Wire·1mo ago
News Placeholder
AN2 Therapeutics to Participate in Fireside Chat at Evercore HealthCONx Conference
AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced...
Business Wire·1mo ago
News Placeholder
Centene stock tumbles after withdrawal of 2025 guidance
Investing.com -- Centene Corporation (NYSE:CNC) stock tumbled 20% after the health insurer withdrew its 2025 earnings guidance, citing unexpected challenges in its Health Insurance Marketplace business and rising Medicaid costs.
investing.com·5mo ago
News Placeholder
As UnitedHealth tumbles, one competitor said they are doing fine
Investing.com -- UnitedHealth (NYSE:UNH) sent shockwaves throughout the managed care sector Thursday after posting weak first quarter results and lowering its full year guidance.  However, for at least one competitor, it is not a “we” problem but a “you” problem.
investing.com·8mo ago
News Placeholder
Elevance Health Q4 earnings miss estimates, stock rises
Investing.com -- Elevance Health Inc. reported fourth quarter earnings that missed analyst expectations, but the health insurer's shares rose following the release.
investing.com·11mo ago

Latest ANTX News

View

Advertisement|Remove ads.

Advertisement|Remove ads.